75000 - Document - Cover
link:presentationLink
link:calculationLink
link:definitionLink
75010 - Statement - Condensed Balance Sheets
link:presentationLink
link:calculationLink
link:definitionLink
75020 - Statement - Condensed Balance Sheets (Parenthetical)
link:presentationLink
link:calculationLink
link:definitionLink
75030 - Statement - Condensed Statements of Operations (Unaudited)
link:presentationLink
link:calculationLink
link:definitionLink
75040 - Statement - Condensed Statements of Changes in Stockholders' Equity (Deficit) (Unaudited)
link:presentationLink
link:calculationLink
link:definitionLink
75050 - Statement - Condensed Statements of Cash Flows (Unaudited)
link:presentationLink
link:calculationLink
link:definitionLink
75060 - Statement - Condensed Statements of Cash Flows (Unaudited) (Parenthetical)
link:presentationLink
link:calculationLink
link:definitionLink
995457 - Disclosure - Organization and Liquidity
link:presentationLink
link:calculationLink
link:definitionLink
995467 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies
link:presentationLink
link:calculationLink
link:definitionLink
995477 - Disclosure - Net Loss Per Common Share
link:presentationLink
link:calculationLink
link:definitionLink
995487 - Disclosure - Investments
link:presentationLink
link:calculationLink
link:definitionLink
995497 - Disclosure - Other Accrued Expenses
link:presentationLink
link:calculationLink
link:definitionLink
995507 - Disclosure - Commitments
link:presentationLink
link:calculationLink
link:definitionLink
995517 - Disclosure - Stockholders' Equity (Deficit)
link:presentationLink
link:calculationLink
link:definitionLink
995527 - Disclosure - Stock-Based Compensation
link:presentationLink
link:calculationLink
link:definitionLink
995537 - Disclosure - Debt
link:presentationLink
link:calculationLink
link:definitionLink
995547 - Disclosure - License Agreement
link:presentationLink
link:calculationLink
link:definitionLink
995557 - Disclosure - Subsequent Events
link:presentationLink
link:calculationLink
link:definitionLink
995567 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies (Policies)
link:presentationLink
link:calculationLink
link:definitionLink
995577 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies (Tables)
link:presentationLink
link:calculationLink
link:definitionLink
995587 - Disclosure - Net Loss Per Common Share (Tables)
link:presentationLink
link:calculationLink
link:definitionLink
995597 - Disclosure - Investments (Tables)
link:presentationLink
link:calculationLink
link:definitionLink
995607 - Disclosure - Other Accrued Expenses (Tables)
link:presentationLink
link:calculationLink
link:definitionLink
995617 - Disclosure - Stockholders' Equity (Deficit) (Tables)
link:presentationLink
link:calculationLink
link:definitionLink
995627 - Disclosure - Stock-Based Compensation (Tables)
link:presentationLink
link:calculationLink
link:definitionLink
995637 - Disclosure - Debt (Tables)
link:presentationLink
link:calculationLink
link:definitionLink
995647 - Disclosure - Organization and Liquidity (Details Narrative)
link:presentationLink
link:calculationLink
link:definitionLink
995657 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies (Details Narrative)
link:presentationLink
link:calculationLink
link:definitionLink
995667 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies - Schedule of Estimated Useful Lives of Property and Equipment (Details)
link:presentationLink
link:calculationLink
link:definitionLink
995677 - Disclosure - Schedule of Potentially-Dilutive Shares Excluded from Diluted Weighted-Average Shares Outstanding (Details)
link:presentationLink
link:calculationLink
link:definitionLink
995687 - Disclosure - Net Loss Per Common Share (Details Narrative)
link:presentationLink
link:calculationLink
link:definitionLink
995697 - Disclosure - Schedule of Investment (Details)
link:presentationLink
link:calculationLink
link:definitionLink
995707 - Disclosure - Schedule of Other Accrued Expenses (Details)
link:presentationLink
link:calculationLink
link:definitionLink
995717 - Disclosure - Commitments (Details Narrative)
link:presentationLink
link:calculationLink
link:definitionLink
995727 - Disclosure - Schedule of Common Stock Warrants Outstanding (Details)
link:presentationLink
link:calculationLink
link:definitionLink
995737 - Disclosure - Stockholders' Equity (Deficit) (Details Narrative)
link:presentationLink
link:calculationLink
link:definitionLink
995747 - Disclosure - Schedule of Stock Options Activity (Details)
link:presentationLink
link:calculationLink
link:definitionLink
995757 - Disclosure - Schedule of Assumptions for Fair Value of Employee And Non-Employee Stock Option (Details)
link:presentationLink
link:calculationLink
link:definitionLink
995767 - Disclosure - Schedule of Restricted Stock Award And Restricted Stock Unit Activity (Details)
link:presentationLink
link:calculationLink
link:definitionLink
995777 - Disclosure - Schedule of Stock-based Compensation Expenses (Details)
link:presentationLink
link:calculationLink
link:definitionLink
995777 - Disclosure - Schedule of Stock-based Compensation Expenses (Details) [Default]
link:presentationLink
link:calculationLink
link:definitionLink
995787 - Disclosure - Stock-Based Compensation (Details Narrative)
link:presentationLink
link:calculationLink
link:definitionLink
995797 - Disclosure - Schedule of Long-term Debt (Details)
link:presentationLink
link:calculationLink
link:definitionLink
995807 - Disclosure - Schedule of Long Term Debt Future Principal Payments (Details)
link:presentationLink
link:calculationLink
link:definitionLink
995817 - Disclosure - Debt (Details Narrative)
link:presentationLink
link:calculationLink
link:definitionLink
995827 - Disclosure - License Agreement (Details Narrative)
link:presentationLink
link:calculationLink
link:definitionLink
999009 - Disclosure - Anchoring
link:presentationLink
link:calculationLink
link:definitionLink
Research and development expense
Research and development expense.
Basis of Presentation and Summary of Significant Accounting Policies
Scenario [Axis]
Warrant expected life
Registration rights
Document Accounting Standard
Schedule of Other Accrued Expenses
Preferred stock, shares issued
Debt
Seven Other Development Milestones [Member]
Seven other development milestones.
Seven Other Development Milestones
Operating Lease, Liability
Operating Lease, Liability, Total
Lease liability
Name
Senior Notes Two Thousand Thirty Two [Member]
Senior notes two thousand thirty two.
Over-Allotment Option [Member]
Stock based compensation expense related to modification
2028
Commitments and contingencies (Note 6)
Weighted average common shares outstanding, diluted
Two Thousand and Thirty Two Notes [Member]
2032 Notes, member.
2032 Notes [Member]
Lessee, Operating Lease, Term of Contract
Lease term
Minimum [Member]
Employee Stock Purchase Plan [Member]
Employee stock purchase plan.
ESPP
Document Registration Statement
Preferred stock, shares outstanding
Employee stock purchase plan description
Employee Stock Ownership Plan (ESOP), Plan Description
Innovatus Life Sciences [Member]
Innovatus Life Sciences [Member]
Common stock, shares issued
Third Amendment to Amended and Restated Loan and Security Agreement [Member]
Third Amendment to Amended and Restated Loan and Security Agreement [Member]
Debt instrument principal amount
Income taxes
Recently Adopted Accounting Pronouncements
Recent Accounting Prononcement Adopted [Policy Text Block]
Finite-Lived Intangible Assets
Intangible Assets, Finite-Lived, Policy [Policy Text Block]
June Two Thousand And Twenty Six Convertible Notes Offering [Member]
June 2026 Convertible Notes Offering [Member]
June 2026 Convertible Notes Offering [Member]
Repayments of Debt
Repayment of debt
Term F Loan [Member]
Term F Loan [Member]
Senior Notes Due Two Thousand And Thirty One Notes [Member]
Senior notes due two thousand and thirty one notes
Senior Notes Due 2031 Notes [Member]
Subsequent Event Type [Domain]
Documents Incorporated by Reference [Text Block]
Lessee, Operating Lease, Liability, Undiscounted Excess Amount
Undiscounted future minimum lease
Weighted-average period
Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Outstanding, Weighted-Average Remaining Contractual Term
Other current assets
Increase (Decrease) in Other Current Assets
Nonoperating Income (Expense)
Other expense, net
Loan Agreement [Member]
Loan Agreement [Member]
Income Statement [Abstract]
Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number
Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period
Less: unamortized debt discount
Discount amount
Debt Instrument, Unamortized Discount, Total
Office and Computer Equipment [Member]
Office and computer equipment.
Office and Computer Equipment [Member]
Related and Nonrelated Parties [Domain]
Net loss per share, basic
Document Period End Date
Amended and Restated Loan Agreement [Member]
Amended and Restated Loan Agreement [Member]
LicenseAgreementTable [Table]
Note payable
Principal amount
Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period
ESPP Expiration period
Purchases of property and equipment
Payments to Acquire Property, Plant, and Equipment
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price
Common stock, shares authorized
Statement of Stockholders' Equity [Abstract]
Prepaid clinical trial costs
Warrants measurement inputs
Document Shell Company Report
Entity Address, Country
Restricted stock vested
Debt Issuance Costs, Current, Net, Total
Proceeds from convertible note payable, net of debt issuance cost and discount
Weighted- average exercise price per share, outstanding
Weighted- average exercise price per share, outstanding
Weighted- average exercise price per share, outstanding.
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsNonOptionsWeightedAverageGrantDateFairValue
Schedule Of Estimated Useful Lives Of Property And Equipment Table Text Block
Schedule of estimated useful lives of property and equipment table text block.
Schedule of Estimated Useful Lives of Property and Equipment
Interest rate
Pre-funded warrant shares
Prefunded warrant, shares.
Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value
Total assets
Assets [Default Label]
Area of Land
Title of 12(b) Security
Preferred stock, $0.001 par value; 2,500,000 shares authorized as of June 30, 2026, and December 31, 2025; 0 shares issued and outstanding as of June 30, 2026, and December 31, 2025
Senior Notes Due Two Thousand And Thirty Two Notes [Member]
Senior notes due two thousand and thirty two notes.
Senior Notes Due 2032 Notes [Member]
Term E Two Loan [Member]
Term E Two Loan [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number
Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number
Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number [Default Label]
Exercise of common stock options, net of shares withheld for exercise price
No Trading Symbol Flag
Schedule of Stock-based Compensation Expenses
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number
Operating Lease, Payments
Initial annual lease payment
Antidilutive Securities, Name [Domain]
Research and Development Arrangement, Contract to Perform for Others, Type [Domain]
Cash paid for interest
First Amendment description
Audited Annual Financial Statements
Options outstanding, weighted average remaining contractual term
Exercise of stock options pending receipt of cash proceeds
Exercise of stock options pending receipt of cash proceeds.
Exercise of common stock options pending receipt of cash proceeds
Stock Issued During Period Shares Conversion Of Preferred Stock To Common Stock Shares
Stock issued during period shares conversion of preferred stock to common stock shares.
Conversion of preferred stock to common stock, shares
Options To Purchase Common Stock [Member]
Options To Purchase Common Stock [Member]
Balance
Total stockholders’ equity
Equity, Attributable to Parent
Total stockholders' equity (deficit)
Entity Address, Address Line Two
Other non-current assets
Collaborative Arrangement and Arrangement Other than Collaborative [Domain]
Net Loss Per Common Share
Fair value of note payable
Gross Unrealized Holding Gains
Remaining stock based compensation expense related to modification
Remaining stock based compensation expense related to modification.
Basis of Presentation
Note payable
Notes Payable, Noncurrent
Total note payable
Total note payable future principal payments
Long-Term Debt
Future payments
Debt issuance costs and discount amortization
Debt Issuance Costs and Discount Amortization
Debt issuance costs and discount amortization.
July 2025 Convertible Notes Offering [Member]
July 2025 Convertible Notes Offering [Member]
Noncash interest income.
NoncashInterestIncome
Non-cash investment (income) expense
Stock, Class of Stock [Table]
Other accrued expenses
Increase (Decrease) in Other Accrued Liabilities
Inventory, Policy [Policy Text Block]
Pre-Launch Inventory
Schedule of Investment
Restricted Stock [Member]
Non-cancelable contractual commitment
Contractual Obligation, Total
Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value
Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value
Document Annual Report
Proceeds from exercise of common stock options
Property, Plant, and Equipment, Useful Life, Term, Description [Extensible Enumeration]
Statistical Measurement [Axis]
Amount of indebtedness eligible to incur under Term D Loan
Entity Interactive Data Current
Expected volatility, maximum
Gain (Loss) on Extinguishment of Debt
Gain (Loss) on Extinguishment of Debt, Total
Loss on debt extinguishment
Loss on debt extinguishment
Loss on debt extinguishment
Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Weighted-average period
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Common stock, $0.001 par value; 95,000,000 shares authorized as of June 30, 2026, and December 31, 2025; 48,922,556 and 48,244,960 shares issued and outstanding as of June 30, 2026, and December 31, 2025, respectively
Property, Plant, and Equipment [Policy Text Block]
Property and Equipment
Entity Public Float
Total liabilities
Liabilities
Lessee, Operating Lease, Discount Rate
Discount rate
Pre Funded Warrant Shares Issued
Pre funded warrant shares issued.
Pre-funded warrant shares
Less: unamortized debt issuance costs
Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net
Prepaid clinical trial costs
Increase (Decrease) in Prepaid Expenses, Other
Equity Option [Member]
Accumulated deficit
Accumulated deficit
Entity Bankruptcy Proceedings, Reporting Current
Exercise of common stock warrants, net of shares withheld for exercise price, shares
Exercise of common stock warrants , shares.
Accounts payable
Increase (Decrease) in Accounts Payable
Total operating expenses
Operating Expenses
Debt Issuance Costs Incurred During Noncash or Partial Noncash Transaction
Debt issuance costs included in other accrued expenses
Warrant purchase price
Common stock price per share
Stock Issued During Period, Shares, Conversion of Units
Converted shares
Trading days
Organization and Liquidity
Changes in operating assets and liabilities:
Interest
Other accrued interest.
Issuance of common stock in an ATM offering, net of issuance costs, shares
Number of Warrants Outstanding
Warrants issued
Debt Instrument, Convertible, Threshold Percentage of Stock Price Trigger
Percentage of stock price
Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Outstanding, Number
Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Other
Written Communications
2017 Employee Stock Purchase Plan [Member]
2017 Employee Stock Purchase Plan [Member]
Risk-free interest rate, maximum
Add: PIK interest (added to principal)
Payment in kind interest debt
Add: PIK interest
Long-Lived Asset, Class [Axis]
2031 Notes [Member]
Two Thousand and Thirty One Note [Member]
2031 notes, member.
Subsequent Events
Disbursement loan amount
Disbursement loan amount.
Senior Notes Two Thousand Thirty One {Member]
Senior notes Two thousand thirty One.
Repayment of note payable
Repayments of Notes Payable
Property, Plant, and Equipment [Line Items]
Contingent loan
Operating lease liabilities, current
Debt Instrument, Fee Amount
Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value
Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value
Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Default Label]
Convertible Notes to Common Stock [Member]
Convertible Notes to Common Stock [Member]
Debt conversion, percentage
Conversion rate
Liabilities and Equity
Total liabilities and stockholders' equity (deficit)
Future Payment for financial covenants
Future Payment for financial covenants
Expected dividend yield
Research and development
Research and development expenses
Research and Development Expense, Total
Entity Voluntary Filers
Estimated Fair Value
Document Fiscal Period Focus
Two Thousand Seventeen Amended And Restated Employee Stock Purchase Plan [Member]
Two thousand seventeen amended and restated employee stock purchase plan.
2017 Amended And Restated Employee Stock Purchase Plan [Member]
Research and development costs
Accrued research and development costs.
Schedule of Assumptions for Fair Value of Employee And Non-Employee Stock Option
Debt instrument interest rate description
Research and Development Arrangement, Contract to Perform for Others, Type [Axis]
Property, Plant, and Equipment [Table]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Sale of Stock [Axis]
Entity Current Reporting Status
Accounting Estimates
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number
Term G Loan [Member]
Term G Loan [Member]
Class of Stock [Domain]
Other
Pre-commencement Tender Offer
Accounts payable
Schedule of Potentially-Dilutive Shares Excluded from Diluted Weighted-Average Shares Outstanding
Financial Instrument [Axis]
Other Reporting Standard Item Number
Name
Document Transition Report
Commitments and Contingencies Disclosure [Abstract]
Class of Warrant or Right [Axis]
Debt Securities, Held-to-Maturity, Allowance for Credit Loss [Line Items]
Current liabilities:
Share-Based Payment Arrangement [Abstract]
Common Stock [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Outstanding, Number
Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Exercised
Investments
Investment [Text Block]
Statistical Measurement [Domain]
Other (expense) income:
Term F Two Loan [Member]
Term F Two Loan [Member]
Stockholders' equity (deficit):
Weighted average common shares outstanding, basic
Assets
Entity Primary SIC Number
Entity Central Index Key
Antidilutive Securities [Axis]
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value
Class of Stock [Line Items]
Other accrued expenses
Current Fiscal Year End Date
Class of Warrant or Right [Domain]
Document Quarterly Report
2016 Plan [Member]
2016 Plan [Member]
2016 Plan [Member]
Entity Address, Address Line Three
Maturity date
Gross Unrealized Holding Losses
Debt Securities, Held-to-Maturity, Accumulated Unrecognized Loss
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Default Label]
Accrued license milestone
Accrued license milestone
Second Amendment To Amended And Restated Loan And Security Agreement [Member]
Second Amendment To Amended And Restated Loan And Security Agreement [Member]
Net cash used in operating activities
Cash Provided by (Used in) Operating Activity, Including Discontinued Operation
Entity Incorporation, State or Country Code
Net loss per share, diluted
Change in common stock, shares reserved for issuance
Change in common stock, shares reserved for issuance
Sale of stock
Dividends
Dividends, Total
Dividends declared
Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Outstanding, Number
Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Expirations
Preferred stock, par value
Net loss
Net loss
Long-Lived Asset, Class [Domain]
Cash, Cash Equivalents, and Short-Term Investments
Cash, Cash Equivalents, and Short-Term Investments, Total
Cash, cash equivalents and short-term investments
Title of 12(g) Security
Debt conversion, number of shares issued
Conversion of Term A Loan outstanding principal to common stock, shares
Scenario [Domain]
Equity Components [Axis]
Accrued clinical trial costs
Accrued clinical trial costs.
Payment on milestone event one
Payment on milestone event one.
Cash flows from investing activities:
Statement of Cash Flows [Abstract]
Unrecognized compensation cost
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price
Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price
Weighted-average grant date fair value of options granted
Intangible Asset, Excluding Goodwill, after Accumulated Amortization
Intangible Asset, Excluding Goodwill, after Accumulated Amortization, Total
Intangible assets, net
TwoThousand And Thirty Two Note Underwriting Agreement [Member]
TwoThousand And Thirty Two Note Underwriting Agreement [Member]
2032 Note Underwriting Agreement [Member]
Pre-commencement Issuer Tender Offer
Increase (Decrease) In Accrued license milestone
Increase (decrease) in accrued license milestone.
Accrued license milestone
Preferred stock, shares authorized
Two thousand and thirty one Note Underwriting Agreement [Member]
Two thousand and thirty one Note Underwriting Agreement [Member]
2031 Note Underwriting Agreement [Member]
Soliciting Material
Final fee percentage
Final fee percentage.
Class of Stock [Axis]
Total
Measurement Input, Expected Term [Member]
The number of additional common stock shares the Underwriters can purchase
Cash paid for operating leases
Cash paid for operating leases.
The cash inflow associated with the amount received from entity's offering of stock to the public
Net proceeds from offering
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price
Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price
Lessee, Operating Lease, Description
Lease description
Conversion price
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number [Default Label]
Short-Term Debt [Line Items]
Short-Term Debt [Table]
License Agreement
Revenue Recognition, Services, Licensing Fees [Policy Text Block]
Investments, All Other Investments [Abstract]
Security Reporting Obligation
Document Type
Six Other Development Milestones [Member]
Six other development milestones.
Six Other Development Milestones
Final fee.
Add: final fee
Cash flows from operating activities:
Liabilities and stockholders' equity (deficit)
Share-Based Payment Arrangement, Option [Member]
Preferred Stock On An As If Converted To Common Stock [Member]
Preferred Stock On An As If Converted To Common Stock [Member]
Subsequent Event [Member]
Loss from operations
Operating Income (Loss)
Measurement Input, Risk Free Interest Rate [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Outstanding, Number
Share price
Common stock price per share
Entity File Number
Equipment [Member]
Lab Equipment [Member]
Location, Statement of Income, Balance [Axis]
Risk-free interest rate, minimum
Long-Lived Assets
Long-Lived Asset, Excluding Intangible Asset and Goodwill, Impairment and Disposal [Policy Text Block]
Retained Earnings [Member]
Accumulated Deficit [Member]
Measurement Input, Expected Dividend Rate [Member]
Entity Registrant Name
Issuance of common stock shares to Pfizer pursuant to an Equity Grant Agreement
Earnings Per Share, Basic, by Common Class, Including Two-Class Method [Table]
Accounting Policies [Abstract]
Depreciation
Debt Instrument, Unamortized Discount (Premium), Net, Total
Debt issuance costs and discount
Selling, general and administrative
Selling, General and Administrative Expense, Total
Net proceeds from loan
License Agreement
License Agreement [Test Block]
License Agreement [Test Block]
Weighted- average exercise price per share, outstanding
Weighted- average exercise price per share, exercised.
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsNonOptionsGrantsInPeriodWeightedAverageExercisedDateFairValue
Entity Address, Address Line One
Other Accrued Expenses
Fair value of the Notes
Extension
Exercise of common stock options, net of shares withheld for exercise price, shares
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number
Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Outstanding, Number
Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Outstanding, Number
Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Outstanding, Number [Default Label]
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price
Total current assets
Assets, Current
Furniture and Fixtures [Member]
Furniture and Fixtures [Member]
Supplemental disclosure of cash flow information:
Entity Small Business
Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value
Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value
Paid After the FDA Approval of an NDA for a Second Indication of Gedatolisib [Member]
Paid after the FDA approval of an NDA for a second indication of Gedatolisib.
Paid After the FDA Approval of an NDA for Second Indication of Gedatolisib
Purchase of intangible assets in accrued license milestone
Purchase Of Intangible Assets In Accrued License Milestone
Purchase of intangible assets in accrued license milestone.
Revision of Prior Period, Adjustment [Member]
Payment for upfront fees
Schedule of Long-term Debt
Consecutive trading days
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Earnings Per Share [Abstract]
Schedule of Stock Options Activity
Proceeds from exercise of common stock warrants
Entity Well-known Seasoned Issuer
Plan Name [Axis]
Subsequent Event Type [Axis]
Equity [Abstract]
Redemption description
Proceeds from convertible notes, net of debt issuance costs of $0 and $40 during the Six months ended June 30, 2026 and 2025, respectively
Proceeds from convertible notes, net of debt issuance costs of $17,584 and $0 during the six months ended June 30, 2026 and 2025, respectively
Stockholders' Equity (Deficit)
Country Region
Two Thousand And Thirty One Underwriting Agreement [Member]
Two thousand and thirty One underwriting agreement member
2031 Underwriting Agreement [Member]
Regulatory milestone
Regulatory milestone.
AccountingPoliciesAbstractTable [Table]
Cash flows from financing activities:
Discount amount
Amortization of Debt Discount (Premium)
2017 Plan [Member]
2017 Plan [Member]
Entity Tax Identification Number
Pre-Funded Warrants [Member]
Pre-Funded Warrants [Member]
Equity Component [Domain]
Stock-based compensation
Entity Address, City or Town
Measurement Input Type [Domain]
Property and equipment included in accounts payable
Capital Expenditures Incurred but Not yet Paid
Entity Common Stock, Shares Outstanding
Proceeds from maturities of investments
Antidilutive Security, Excluded EPS Calculation [Table]
Lessee, Operating Lease, Option to Extend
Lease option to extend
Statement [Table]
Stock-based compensation, shares
Development milestone
Development milestone.
Development milestone
Net loss before income taxes
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest
Amendment Description
Entity Shell Company
Expected life (years)
Cash Provided by (Used in) Investing Activity, Including Discontinued Operation
Net cash provided by (used in) investing activities
Statement [Line Items]
Commitments
Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number
Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period
Maximum [Member]
Term E Loan [Member]
Term E Loan [Member]
Debt Disclosure [Abstract]
Sale of Stock [Domain]
Interest income
Term A Loan [Member]
Term A Loan [Member]
Debt Conversion, Converted Instrument, Amount
Conversion of Term A Loan to shares of common stock
Conversion of Term A Loan outstanding principal to common stock
Name
Exercise of common stock warrants, net of shares withheld for exercise price
Exercise of common stock warrants.
Net change in cash and cash equivalents
Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Period Increase (Decrease), Excluding Exchange Rate Effect, Including Discontinued Operation
Document Period Start Date
Subsequent Events [Abstract]
Paid After the FDA Approval of an NDA for Gedatolisib [Member]
Paid after the FDA approval of an NDA for gedatolisib.
Paid After FDA Approval of an NDA for Gedatolisib
Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value
Amortization of Debt Issuance Costs
Amortization of issuance costs
Current assets:
Consulting and professional fees
Name
Convertible notes
Convertible Debt, Noncurrent
Document Fiscal Year Focus
Schedule of Common Stock Warrants Outstanding
Common stock, shares outstanding
Collaborative Arrangement and Arrangement Other than Collaborative [Table]
Financial Instruments [Domain]
Non-cash operating lease expense
Noncash operating lease expense net.
Amendment fee payable
Amendment fee.
Forecast [Member]
Elected Not To Use the Extended Transition Period
Weighted- average exercise price per share, outstanding
Weighted- average exercise price per share, expired.
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsNonOptionsGrantsInPeriodWeightedAverageExpiredDateFairValue
Commercial milestones
Commercial milestones.
Commercial milestones
Term D Loan [Member]
Term D Loan [Member]
Operating Lease, Liability, Noncurrent
Operating lease liabilities, non-current
Revision of Prior Period [Domain]
Stock Issued During Period Value Conversion Of Preferred Stock To Common Stock
Stock issued during period value conversion of preferred stock to common stock.
Conversion of preferred stock to common stock
License Agreement
Disclosure License Agreement Abstract
Other accrued liabilities, current
Other Accrued Liabilities, Current
Security Exchange Name
Measurement Input Type [Axis]
Related and Nonrelated Parties [Axis]
Recent Accounting Pronouncements Not Yet Adopted
Recently Adopted Accounting Pronouncements
Warrant [Member]
Class of warrant exercise price
Warrants exercise price per share
Entity Address, State or Province
Expected volatility, minimum
Series A Preferred Stock [Member]
Number of shares available for issuance
Payment-in-kind interest
Operating lease right-of-use assets
Right-of-use asset
Amendment Flag
Right-of-Use Asset Obtained in Exchange for Operating Lease Liability
Right-of-use asset obtained in exchange for operating lease liability
Stock-Based Compensation
Interest expense
Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table]
Debt Instrument [Axis]
Secondary Registration Statement Costs Included In Accounts Payable
Secondary registration statement costs included in accounts payable.
Secondary registration statement costs included in accounts payable
City Area Code
Stock Issued During Period, Value, Employee Stock Purchase Plan
Employee stock purchases
Interest expense
Interest Expense, Nonoperating
Debt Securities, Held-to-Maturity, Allowance for Credit Loss [Table]
Preferred Stock [Member]
Pfizer License Agreement [Member]
Pfizer License Agreement [Member]
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Operating expenses:
Principal amount
Conversion of Stock, Amount Converted
Weighted- average exercise price per share, outstanding
Weighted- average exercise price per share, issued.
Employee compensation and benefits
Common stock, par value
Aggregate value of milestone events
Aggregate value of milestone events
Cash and cash equivalents:
Options exercisable, weighted average remaining contractual term
Conversion percentage
Total current liabilities
Liabilities, Current
Beginning of period
End of period
Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Including Discontinued Operation
License Agreement [Member]
License Agreement [Member]
Debt final fee percentage
Debt final fee percentage.
Collaborative Arrangement and Arrangement Other than Collaborative [Axis]
2029
Trading Symbol
Amortization of debt issuance costs and discount
Amortization of Debt Issuance Costs and Discounts, Total
Debt issuance costs and discount amortization
Accrue interest payable rate
Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number
Entity Emerging Growth Company
Additional Paid-in Capital [Member]
Weighted- average exercise price per share, outstanding
Weighted- average exercise price per share, surrendered upon cashless exercise.
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsNonOptionsGrantsInPeriodWeightedAverageSurrenderedUponCashlessExerciseDateFairValue
Plan Name [Domain]
Selling, General and Administrative
Purchases of capitalized software
Payments for Software
Warrants To Purchase Common Stock [Member]
Warrants To Purchase Common Stock [Member]
Stock Issued During Period, Shares, Employee Stock Purchase Plans
Employee stock purchases, shares
US Treasury Securities [Member]
Measurement Input, Price Volatility [Member]
Total intrinsic value of options exercised
Revision of Prior Period [Axis]
Document Shell Company Event Date
Annual Information Form
Supplemental disclosures of non-cash investing and financing activities:
Cover [Abstract]
Schedule of Restricted Stock Award And Restricted Stock Unit Activity
Purchases of investments
Payments to Acquire Investments
Amended And Restated Two Thousand Seventeen employee stock purchase plan [Member]
Amended And Restated Two Thousand Seventeen employee stock purchase plan [Member]
Amended and Restated 2017 Employee Stock Purchase Plan [Member]
Paid After the FDA Filing of an NDA for gedatolisib [Member]
Paid after the FDA filing of an NDA for gedatolisib.
Paid After FDA Filing of an NDA for Gedatolisib
Number of shares reserved for issuance description
Accrued clinical trial costs
Increase decrease in accrued clinical trial costs.
IncreaseDecreaseInAccruedClinicalTrialCosts
Property, Plant, and Equipment, Useful Life
Estimated useful life
Stock-based compensation
Stock-based compensation expense
Additional paid-in capital
Securities Purchase Agreement [Member]
Securities Purchase Agreement [Member]
Adjustments to reconcile net loss to net cash and cash equivalents used in operations:
Investments
Amortized Cost, as Adjusted
Cash and cash equivalents
Payments of Debt Issuance Costs
Payments for debt issuance costs
Accumulated Other Comprehensive Income (Loss) [Table]
Net cash provided by financing activities
Cash Provided by (Used in) Financing Activity, Including Discontinued Operation
Payments for secondary registration statement costs
Payments for secondary registration statement costs.
PaymentsForSecondaryRegistrationStatementCosts
Payables and Accruals [Abstract]
Proceeds from employee stock purchases
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period
Entity Filer Category
Debt Instrument, Name [Domain]
Property and equipment, net
Balance, shares
Balance, shares
Shares, Outstanding
July 2025 Equity Offering [Member]
July 2025 Equity Offering [Member]
Other current assets
Entity Address, Postal Zip Code
Statement of Financial Position [Abstract]
Local Phone Number